• Return to Headlines

Clovis Oncology: The Losing Streak Continues (CLVS)

By Shiri Gupta

Shares of Clovis Oncology (NASDAQ:CLVS) traded today at $27.72, breaking its 52-week low. Approximately 183,000 shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares.

Clovis Oncology Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis target its development programs for the treatment of specific subsets of cancer populations.

In the past 52 weeks, Clovis Oncology share prices have been bracketed by a current low of $27.72 and a high of $86.26 and are now at $27.72. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 1.1%.

There is potential upside of 183.4% for shares of Clovis Oncology based on a current price of $27.72 and an average consensus analyst price target of $78.57. The stock should find initial resistance at its 50-day moving average (MA) of $34.07 and further resistance at its 200-day MA of $48.11.

SmarTrend recommended that its subscribers protect gains by selling shares of Clovis Oncology on July 25th, 2018 by issuing a Downtrend alert when the shares were trading at $44.69. Since that call, shares of Clovis Oncology have fallen 36.5%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: 52 week high/lows clovis oncology

Ticker(s): CLVS